Actinium Pharmaceuticals (Delaware) Insider Trades
NYSE: ATNMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 0 · $0
- Sales
- 0 · $0
- Shares bought / sold
- 0 / 0
- Net activity
- Net buying $0
Actinium Pharmaceuticals (Delaware) insider activity
Over the last 12 months, Actinium Pharmaceuticals (Delaware) insiders reported 8 transactions on SEC Form 4: 0 open-market purchases and 0 sales. The most recent filing shows David Matthew T (Chief Financial Officer) reporting a transaction in 250,000 shares on Oct 14, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put ATNM's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
ATNM insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Oct 14, 2026 | David Matthew TChief Financial Officer | Award | 250,000 | — | Form 4 |
| Sep 2, 2026 | Steinhart Richard IDirector | Award | 62,800 | — | Form 4 |
| Sep 2, 2026 | SETH SANDESHChief Executive Officer | Award | 1,027,274 | — | Form 4 |
| Sep 2, 2026 | SETH SANDESHChief Executive Officer | Award | 753,600 | — | Form 4 |
| Sep 2, 2026 | Almenoff June SherieDirector | Award | 18,000 | — | Form 4 |
| Sep 2, 2026 | Chell Jeffrey W.Director | Award | 61,600 | — | Form 4 |
| Sep 2, 2026 | Nicholson, C. DavidDirector | Award | 62,800 | — | Form 4 |
| Sep 2, 2026 | Shetty AjitDirector | Award | 61,600 | — | Form 4 |
| Aug 18, 2025 | SETH SANDESHChief Executive Officer | Tax withholding | 120,900 | $206.74K | Form 4 |
| Aug 17, 2022 | SETH SANDESHChief Executive Officer | Award | 300,000 | — | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4